Rintatolimod
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Rintatolimod
- DrugBank Accession Number
- DB16425
- Background
Not Available
- Type
- Biotech
- Groups
- Experimental
- Biologic Classification
- Gene Therapies
Other gene therapies - Synonyms
- 5'-INOSINIC ACID, HOMOPOLYMER, COMPLEX WITH 5'-CYTIDYLIC ACID POLYMER WITH 5'-URIDYLIC ACID (1:1)
- Poly I: Poly C12U
- POLY(5')-INOSINYL-(3'->) DUPLEX WITH POLY(DODECAKIS(3')-CYTIDYLYL-(5'->)3')-URIDYLYL-(5'->)
- Poly(C12U)
- Poly(I):poly(C12U)
- Rintatolimod
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Ampligen / Atvogen
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 94325AJ25N
- CAS number
- 38640-92-5
References
- General References
- Not Available
- External Links
- Wikipedia
- Rintatolimod
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME) 1 2 Completed Treatment Hepatic Metastases / Recurrent Colorectal Carcinoma / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v7 1 2 Completed Treatment HIV Seropositivity / Human Immunodeficiency Virus (HIV) Infections 1 2 Completed Treatment Post COVID-19 Condition / Post-acute COVID-19 (PACS), or "Long COVID" Syndrome 1 2 Recruiting Treatment HLA-A2 Positive Cells Present / Refractory Melanoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at January 13, 2021 18:34 / Updated at July 18, 2023 22:58